Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)
National Institute of Environmental Health Sciences (NIEHS)
National Cancer Institute (NCI)
This Notice is to inform the research community that the National Institutes of Health (NIH) Tobacco Regulatory Science Program (TRSP), participating NIH Institutes and Centers (ICs), and the United States Food and Drug Administration (FDA) Center for Tobacco Products (CTP) intend to reissue the Funding Opportunity Announcement (FOA) RFA-OD-19-021 "Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)." When reissued, this FOA will continue to utilize the R21 grant mechanism.
Modifications to this FOA include funding as NIH, via NIH support from the FDA Center for Tobacco Products (CTP), intends to fund up to 5 R21s, corresponding to a total of up to $1.0 million, for fiscal year 2021. Future year amounts will depend on availability of funds.
This Notice is being provided to allow potential eligible applicants sufficient time to develop competitive and responsive projects.
The FOA is expected to be published in Spring 2021. Details of the planned FOA are provided below.
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute’s (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available repositories would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.
NIH, via support from the FDA Center for Tobacco products (CTP), intends to fund up to 5 R21s, corresponding to a total of up to $1 million, for fiscal year 2021. Future year amounts will depend on availability of funds.
The combined budget for direct costs for the entire project period may not exceed $275,000. No more than $200,000 in direct cost may be requested in any single year.
Applications are not being solicited at this time.
Please direct all inquiries to:
Tobacco Regulatory Science Program
Office of Disease Prevention